| abstract |
In a preparation containing solifenacin or a salt thereof, it has been elucidated that the amorphous substance is the cause of the degradation of the main drug over time, and therefore, in providing a solid preparation of solifenacin or a salt thereof to the clinical site, Of a stable solid formulation of solifenacin or a salt thereof capable of suppressing general degradation. A pharmaceutical composition for solid preparations comprising solifenacin and an amorphization inhibitor, wherein the amorphization inhibitor is a substance having an ethylene oxide chain such as polyethylene glycol. [Selection figure] None |